Abstract
Immunotherapy with checkpoint blockade represents the standard therapy for multiple malignancies, including melanoma, NSCLC, cHL, renal cell carcinoma (RCC), bladder cancer, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), Merkel cell carcinoma, colorectal cancer (CRC) with microsatellite instability high (MSI-H) or DNA mismatch repair deficient (dMMR), and so forth. Along with the examples presented in the previous chapters, herein we report some additional case reports illustrating response to immunotherapy in other tumor types.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wu X, Gu Z, Chen Y, et al. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J. 2019;17:661–74. https://doi.org/10.1016/j.csbj.2019.03.006. eCollection 2019.
Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374–85.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67.
Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182–91.
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Lopci, E., Castello, A. (2020). Other Tumor Types: 18F-FDG PET/CT for Response Assessment of Various Tumors Following Immunotherapy. In: Lopci, E., Fanti, S. (eds) Atlas of Response to Immunotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-31113-1_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-31113-1_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-31112-4
Online ISBN: 978-3-030-31113-1
eBook Packages: MedicineMedicine (R0)